Immuron Ltd Files September 2025 6-K Report

Ticker: IMRN · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1660046

Immuron LTD 6-K Filing Summary
FieldDetail
CompanyImmuron LTD (IMRN)
Form Type6-K
Filed DateSep 30, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory-filing, foreign-private-issuer

TL;DR

Immuron Ltd filed its 6-K for Sept 2025, including auditor consent. Standard disclosure.

AI Summary

Immuron Limited filed a Form 6-K on September 30, 2025, reporting information for the month of September 2025. The filing includes an auditor's consent as Exhibit 23.1. Immuron Limited is a foreign private issuer incorporated in Australia and is subject to reporting requirements under the 1934 Act.

Why It Matters

This filing provides routine updates and disclosures for Immuron Ltd, a biopharmaceutical company, which may be relevant for investors tracking its compliance and operational information.

Risk Assessment

Risk Level: low — This is a routine Form 6-K filing for Immuron Ltd, primarily containing an auditor's consent and standard disclosures, with no immediate material financial or operational changes indicated.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that is furnished to the SEC to provide information that the company has made or is required to make public in its home country, filed with a stock exchange, or distributed to its security holders.

What specific information is included in this Immuron Ltd 6-K filing?

This filing specifically mentions that an Auditor's Consent is attached as Exhibit 23.1.

What is Immuron Ltd's principal executive office address?

Immuron Ltd's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.

Does Immuron Ltd file annual reports under Form 20-F or Form 40-F?

Immuron Ltd indicates that it files annual reports under cover of Form 20-F.

What is Immuron Ltd's SIC code?

Immuron Ltd's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 296 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-09-30 08:07:19

Filing Documents

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Auditors Consent Attached as Exhibit 23.1 to this report on Form 6-K is the Consent of Grant Thornton Audit Pty Ltd, independent registered accounting firm to Immuron Limited, dated September 30, 2025. The information contained in Exhibit 23.1 shall be deemed to be incorporated by reference into Immuron Limited’s registration statement on Form F-3 (File Nos. 333-280667), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBITS Exhibit Number Description 23.1 Consent of Grant Thornton Audit Pty Ltd 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: September 30, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing